Johnson & Johnson's SGLT2 inhibitor Invokana (canagliflozin)--among a handful of drugs in the new category of DPP-4 drugs for diabetes--not only took a big jump in sales for the first quarter but also made some significant market-share gains.
It was a hard-fought battle between heavyweights for the #FierceMadness crown. For two tense days, the lead swung back and forth between contenders, with the tournament title hanging in the balance. Heading into the final day of voting, Trulicity boasted a hefty lead. Could top-seeded Vimizim claw its way back to the top to snatch the 2015 Drug Name Tournament championship? Which drug would bring home the glory? Read more >>
Suspicions are confirmed: Pharma's spending on ads took a flying leap last year. By Kantar Media's numbers, direct-to-consumer ad spend hit $4.53 billion in 2014, up about 18% from $3.83 billion in 2013. Read more >>
Less than a year ago, Arena marketing partner Eisai pledged to add another 200 staffers to its rep army for obesity therapy Belviq, bringing the total force to 600. Now, though, the Japanese pharma is doing some stateside job-trimming, and the restructuring will affect Arena's med, too.
It's no secret that technology is transforming healthcare. But Big Pharma? Not quite yet. Some risk-averse drugmakers have been slow to adopt the digital lifestyle.
The glory days for Pfizer's Viagra are winding down in the U.S., and now, another generics company has the go-ahead to help pave the way for the drug's demise.
Almost one-quarter (21%) of respondents in a recent survey said they talk to a doctor about a drug or treatment after watching a TV ad. The survey, taken by pharma analytics firm Treato.com on its website, found that an additional 5.8% suggest the treatment to someone else after viewing an ad.
AstraZeneca dodged a bullet Tuesday, when an FDA panel of experts almost unanimously backed Onglyza's cardiovascular safety. But the committee did recommend that the label of the diabetes therapy feature information about a potential risk of heart failure.
When Pfizer teamed up with Merck KGaA on lung cancer, the headlines zeroed in on the sexiest part of the $2.85 billion deal: their immuno-oncology plans. The two companies will work together on cancer-fighters in the PD-L1 arena, one of the hottest fields in pharma these days, including a Phase II Merck drug.